Congenital Hip Dysplasia
42
2
12
12
Key Insights
Highlights
Success Rate
43% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
38.1%
16 terminated out of 42 trials
42.9%
-43.7% vs benchmark
43%
18 trials in Phase 3/4
25%
3 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 12 completed trials
Clinical Trials (42)
Manual Intervention and Congenital Hip Dysplasia in Infants
Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip
A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System
Avenir® Cemented Hip Stem - PMCF
Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component
The Medacta International SMS Post-Marketing Surveillance Study
Prospective Study for the Evaluation of the Cementless Anatomic Femoral Stem Minimax -Launay
The Medacta Quadra-P Anteverted Study
Actis Total Hip System 2 Year Follow-up
Exception Cementless Hip Stem
PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty
The Medacta International AMIStem-P Post-Marketing Surveillance Study
Vivacit-E Post-market Follow-up Study
AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study
Global Hip Dysplasia Registry
AVANTAGE® RELOAD Double Mobility Acetabular Cup -Clinical Study
Pelvic Osteotomy Of The Total Hip Replacement
A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup
Pericapsular Nerve Group (PENG) Block for Congenital Hip Dislocation Surgery
Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System